KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Assets: 2009-2024

Historic Assets for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $37.8 billion.

  • Regeneron Pharmaceuticals' Assets rose 7.28% to $40.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $40.2 billion, marking a year-over-year increase of 7.28%. This contributed to the annual value of $37.8 billion for FY2024, which is 14.15% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Assets of $37.8 billion as of FY2024, which was up 14.15% from $33.1 billion recorded in FY2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Assets peaked at $37.8 billion during FY2024, and registered a low of $17.2 billion during FY2020.
  • Moreover, its 3-year median value for Assets was $33.1 billion (2023), whereas its average is $33.4 billion.
  • Data for Regeneron Pharmaceuticals' Assets shows a peak YoY soared of 48.19% (in 2021) over the last 5 years.
  • Regeneron Pharmaceuticals' Assets (Yearly) stood at $17.2 billion in 2020, then surged by 48.19% to $25.4 billion in 2021, then grew by 14.86% to $29.2 billion in 2022, then increased by 13.23% to $33.1 billion in 2023, then rose by 14.15% to $37.8 billion in 2024.